| Code | CSB-RA004847MB2HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to Imzokitug, targeting the C-C chemokine receptor type 8 (CCR8), a G protein-coupled receptor predominantly expressed on regulatory T cells (Tregs) and type 2 helper T cells. CCR8 plays a critical role in immune regulation by mediating chemotaxis in response to its ligands CCL1 and CCL18, directing Treg migration to tumor microenvironments and inflammatory sites. The receptor's preferential expression on intratumoral Tregs has established it as a significant target in immuno-oncology research, particularly in understanding tumor immune evasion mechanisms and the immunosuppressive microenvironment across various solid tumors.
Imzokitug represents a therapeutic antibody designed to deplete CCR8-positive Tregs through antibody-dependent cellular cytotoxicity, currently under investigation for cancer immunotherapy applications. This biosimilar antibody provides researchers with a valuable tool for investigating CCR8-mediated immune regulation, exploring Treg biology, and studying potential therapeutic interventions in oncology and autoimmune disease models. It supports investigations into tumor immunology, chemokine receptor signaling pathways, and the development of novel immunotherapeutic strategies.
There are currently no reviews for this product.